

LSP Life Sciences Fund N.V.

Report on the first half of 2017

LSP LIFE SCIENCES FUND N.V.

(no audit or limited review is performed)

Report on the first half of
2017

Visiting address

Johannes Vermeerplein 9
1071 DV Amsterdam
The Netherlands

Website

www.lspvc.com/funds/public.html

Fund Manager

LSP Advisory B.V.
Johannes Vermeerplein 9
1071 DV Amsterdam
The Netherlands

Legal and Tax advisor

Clifford Chance LLP
Droogbak 1a
1013 GE Amsterdam
The Netherlands

Fund Agent and Administrator

KAS BANK N.V.
Nieuwezijds Voorburgwal 225
1012 RL Amsterdam
The Netherlands

Custody Bank

KAS BANK N.V.
Nieuwezijds Voorburgwal 225
1012 RL Amsterdam
The Netherlands

Depository

KAS Trust & Depository Services B.V.
Nieuwezijds Voorburgwal 225
1012 RL Amsterdam
The Netherlands

Auditor

KPMG Accountants N.V.
Laan van Langerhuize 1
1186 DS Amstelveen
The Netherlands

CONTENTS

PROFILE.....	4
DIRECTOR'S REPORT	6
BALANCE SHEET on 30 June 2017	9
PROFIT AND LOSS ACCOUNT for the period of 1 January – 30 June 2017.....	10
CASH FLOW STATEMENT for the period of 1 January – 30 June 2017.....	11
SELECTED NOTES TO THE REPORT ON THE FIRST HALF OF 2017	12
OTHER INFORMATION.....	29
STATEMENT OF THE DEPOSITARY.....	30

PROFILE

General information

LSP Life Sciences Fund N.V. (the Fund) is a public company with the status of an investment company with variable capital organised and established under the laws of the Netherlands on 18 April 2011. The Fund has its statutory seat in Amsterdam, the Netherlands and is registered at the Trade Register of the Chamber of Commerce in Amsterdam under file number 52545474. The Fund is an open-end investment fund listed on Euronext Amsterdam. The Fund qualifies as a tax-exempt investment fund within the meaning of article 6a of the Dutch corporate income tax act. Accordingly, the Fund is not subject to Dutch corporate income tax.

Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical, specialist pharmaceutical, medical device, drug delivery, vaccine and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with the balance invested in US companies. The Fund targets to invest in the small- and –mid-cap segment. The Fund Manager believes that in particular this sub-segment of companies offers great potential for value growth. Typically, these companies will have developed a suite of innovative technologies that offer benefit over existing technologies and approaches. In addition, these companies have frequently established a product development pipeline that consists of therapeutics that have the potential to offer clinical benefit to a large and/or underserved market. The Fund intends to specifically target those companies that are projected to realize important clinical, regulatory or commercial milestones, value-enhancing partnerships and/or offer M&A potential. By doing so, the Fund expects to benefit from the value increases that frequently accompany the announcement of such milestones, partnerships or M&A transactions.

Sustainable and responsible investing (SRI)

Sustainable and responsible investing means giving due consideration to environmental, social and governance (ESG) investment risks and opportunities – the pillars of the Sustainability model. The Fund uses these Sustainability measures, combined with more traditional methods of financial and company evaluation methods, to identify the very best investment opportunities.

The due diligence process of the Fund is structured and well-validated in the selection of companies with the 'best-in-class' approach within sub-sectors of our target market. On a macro level, an assessment is performed of the key need for the products which are the core assets of the company, the competitive environment in which the companies operate as well as of potential future developments which may impact the sustainability of the company's approach. On a company specific level, the key medical benefits of each of the products within the portfolio and their potential social and environmental impact are analysed. Furthermore the quality of management and their approach to corporate governance issues which may impact the company's reputation and investor confidence are reviewed as part of the due diligence process.

By focusing on sustainable investments in life sciences companies, the Fund believes that its investments help to support the development of all manner of medical innovation which could promote a better quality of life and increase life expectancy. In developing drugs, vaccines and other solutions for unmet medical needs or expanding the availability of medications, companies within the life sciences sector help to keep people healthier for longer, thereby improving productivity through reduced sick leave and reducing the burden on the healthcare system and society.

Fund Governance

The Fund is managed by LSP Advisory B.V. as sole managing director of the Fund. LSP Advisory B.V. is a wholly owned subsidiary of LSP Advisory Group B.V.

The Fund Manager is responsible for the entire management of the Fund in accordance with the provisions of the Fund's organizational documents and applicable laws. The investment team of the Fund Manager consists of three individuals - Mark Wegter, Joep Muijters and Geraldine O' Keeffe – who have complementary investment skills and backgrounds relevant to the Fund's business. The investment team is supported by Edwin van den Broek as its Senior Trader.

The investment team receives full support from the in-depth industry knowledge of the entire cross-Atlantic and pan-European LSP organization. The Fund Manager is further supported by LSP's established, global network of advisors and experts who bring specific expertise essential for performing in-depth due diligence on potential and existing investee companies.

The Fund Manager has been granted a license pursuant to Article 2:65 of the Dutch Financial Markets Supervision Act (Wft) by the Authority for the Financial Markets on 12 April 2011.

The Supervisory Board of the Fund comprises Pauline Bieringa and Onno Paymans, both having relevant expertise on the Fund's business. The principal duties and responsibilities of the Supervisory Board include (i) the supervision of the management of the Fund as performed by the Fund Manager as well as to supervise the general course of affairs of the Fund, and (ii) resolving any conflict of interest situation the Fund is involved in.

DIRECTOR'S REPORT

Investment Performance

As per the end of June 2017, the Fund has been operational for over six years and has shown strong performance over that period. After 2016 had proven to be challenging for the healthcare sector as a whole driven primarily by the uncertainty around drug pricing in the US coupled to the uncertain outcome of the US Presidential elections, 2017 has seen a very good first half. As a result, the Net Asset Value per share moved from Euro 169.37 as at 31 December 2016 to Euro 212.92 (plus 25.7%) as at 30 June 2017. The Fund recorded a profit for the period of Euro 14.6 million compared to a loss of Euro 18.7 million in the first half of last year. As outlined in the prospectus, the Fund aims to provide absolute return for its investors. The Fund Manager is of the opinion that there is no proper benchmark available, which can be used to evaluate the Fund's performance. Therefore, no comparative benchmark data is presented in this report. Importantly, we focus to a lesser extent on short term investment opportunities and remain true to our strategy of building a balanced portfolio with investments that offer upside in the mid- to long term (on average 1 to 2 years). Our portfolio primarily holds investments in companies that have a market cap below Euro 2.5 billion. As at 30 June 2017 the value of the portfolio amounted to Euro 62.5 million holding 16 names (2016: 17 names).

The portfolio consists exclusively of equity (-derived) positions in listed life sciences companies that jointly provide a balanced - yet concentrated - exposure to the sector. Investments have been spread across clinical stage of development, disease area, geography, field of technology and business model. The majority of the investments in the period were in the area of drug development, combined with investments in innovative diagnostics, medical devices and specialty pharma companies. Equity stakes were predominantly below 5% of the portfolio company's outstanding capital, the exact size depending on company specific factors such as liquidity, market capitalization, timing of expected news flow and long term outlook. Holding periods consequently varied. The monthly reports of the Fund that are published on the Fund's website include the current portfolio composition and also list the top-5 best performing stocks of the respective month.

Alternative Investment Fund Managers Directive

The Fund Manager has implemented the Alternative Investment Fund Managers Directive (AIFMD) that came into force on 22 July 2014. Furthermore it has appointed KAS Trust & Depositary Services B.V. as Depositary for the Fund in accordance with the directive. The Depositary is responsible for the (i) the safekeeping of the Fund's assets, and (ii) the oversight and supervision of the Fund and the management of the Fund by the Fund Manager. The Depositary has delegated its day-to-day custody tasks to KAS BANK N.V. The depositary remains liable towards the Fund for loss of assets of which the custody has been delegated to KAS BANK N.V. or another third party. The Depositary can only discharge itself from such liability if all the requirements of article 21(13) or 21(14) of the AIFMD are met.

Fund's risk management

The Fund has exposure to market risks, liquidity risk, credit risk, counterparty risk and operational risks, including preservation and legal and tax compliance risks. The Fund Manager applies a comprehensive process based on qualitative and quantitative risk measures to assess the risks of the Fund entailing a standard monitoring process which consists of pre-defined monitoring items and cycles. The overall exposure of the Fund is calculated by means of the Value-at-Risk (VaR) methodology.

Fund policy regarding voting rights and voting conduct

The Fund Manager will actively exercise, or deliberately refrain from exercising, voting rights attached to the Fund's shares in its portfolio companies. The Fund Manager will determine the manner in which voting rights are being exercised on a case-by-case basis, but at all times in the best interests of the Fund and the investors of the Fund. During the first half of 2017 the Fund Manager exercised its voting rights on one occasion.

Human resources

The Fund does not employ any personnel. The management of the Fund is entrusted to the Fund Manager.

Administrative organization and internal controls

The Fund Manager and the Fund have documented the administrative organization and internal controls in accordance with the Dutch Financial Markets Supervision Act (Wft) and the Decree on Market Conduct Supervision of Financial Business (Bgfo). During the reporting period we have reviewed the various aspects of our operations. Our review did not find anything that would lead us to conclude that the administrative organization and the system of internal controls as referenced in article 121 of the Bgfo does not satisfy the requirements as laid down in the Bgfo and related regulations. Furthermore, we did not find that the administrative organization and internal controls are ineffective or that they do not operate in accordance with their description.

Based on the above, we declare as Fund Manager of the LSP Life Sciences Fund N.V. that we are in possession of a description of the administrative organization and internal controls in accordance with Article 121 of the Bgfo, which fulfils the requirements of the Bgfo. We also state with a reasonable degree of certainty that the administrative organization and the system of internal controls were effective and operated in accordance with its description during the reporting period.

The director of LSP Life Sciences Fund N.V. confirms to the best of its knowledge that:

- the financial statements for the first half of 2017 have been prepared in accordance with the statutory provisions of Part 9, Book 2 of the Netherlands Civil Code as well as the Dutch Act on Financial Supervision and give a true and fair view of the assets, liabilities and financial position of LSP Life Sciences Fund N.V. as at 30 June 2017 and of its result for the period then ended;
- the report includes a fair review of the key developments of the Fund during the period and the effects thereof on the annual report, together with the principal risks and uncertainties of upcoming six months;
- the report provides adequate disclosure of the principal transactions with related parties.

Outlook

While we have seen little clarity on the future of the ‘repeal and replace’ of the Affordable Healthcare Act (more commonly known as ACA or Obamacare) or on drug pricing, the market seems to be much less concerned. From a healthcare industry perspective, President Trump’s top healthcare appointees have been sound. Tom Price seems a very sensible appointment as head of the Department of Health and Human Services (HHS). He has in-depth knowledge of how the healthcare system works. Scott Gottlieb the new chief at FDA, understand the industry from many perspectives and even has prior experience at FDA. He is a strong advocate of streamlining processes at FDA in order to bring new treatments to patients faster. His plan to decrease the overall cost of healthcare is to speed the approval process for generic drugs – more generics on the market means increased pricing pressure. Simple generics manufacture is not a sub-sector in which the LSP fund invests. All attempts to repeal ACA thus far have failed. There will be further attempts and change will come, however, a complete repeal looks increasingly unlikely. A ‘replace’ will probably not be too dramatically different from the current ACA. With regard to drug pricing – a very hot topic – nothing has happened! It was signalled to the market that an Executive Order from the President on drug pricing was imminent – but that was a few months ago already. There has been no further update. Taken together – all these various factors appear to have calmed market concerns. There will be changes to ACA and there will be increased scrutiny on drug prices – but that is part of the industry. The healthcare indices have rebounded from their mid-16 lows – both a market correction and driven by positive news flow from the sector. Solid 1H financials from the large pharmaceutical and large biotech companies have also helped to increase market confidence. M&A – considered a bell weather for the healthcare market sentiment - has started to increase. There are at least 63 product related events (such as clinical trial data or FDA approval) anticipated between now and the end of 2017 in addition to financial reports and company updates. The outcomes will not all be positive – but at least now we are operating in a market which is rewarding success.

The director

LSP Advisory B.V.

Mark Wegter

Joep Muijers

Geraldine O’Keeffe

BALANCE SHEET on 30 June 2017

(in thousands of Euro's, before appropriation of the result)
(no audit or limited review is performed)

	Note	30 June 2017	31 December 2016
Assets			
Investments	1		
Investments in securities		62,476	42,653
		62,476	42,653
Receivables			
Amounts receivable		1,768	300
Other assets	2		
Cash accounts		3,479	17,041
Total Assets		67,723	59,994
Liabilities and shareholders' equity			
Shareholders' equity	3		
Issued share capital		315	353
Share premium		24,499	31,747
Other reserves		27,683	45,950
Unappropriated result		14,641	-18,267
		67,138	59,783
Current liabilities	4		
Creditors and accrued expenses		585	211
Total Liabilities and shareholders' equity		67,723	59,994
Net Asset Value per share		212.92	169.37

PROFIT AND LOSS ACCOUNT for the period of 1 January – 30 June 2017

(in thousands of Euro's)
(no audit or limited review is performed)

	Note	30 June 2017	30 June 2016
Income from investments			
Dividends on securities		10	-16
Realized movements in investments and other assets 5			
Realized movements on securities		5,004	-10,750
		5,004	-10,750
Unrealized movements in investments and other assets 5			
Unrealized movements on securities		8,236	-8,709
Currency results on cash accounts		2,389	1,798
		10,625	-6,911
Expenses			
Management costs	6	542	576
Depositary costs	7	18	8
Fund operational costs	8	166	147
Interest expenses on cash accounts		272	247
		998	978
Result for the period		14,641	-18,655

CASH FLOW STATEMENT for the period 1 January – 30 June 2017

(in thousands of Euro's)

(no audit or limited review is performed)

	30 June 2017	30 June 2016
Cash flows from investment activities		
Net result	14,641	-18,655
Realized movements in investments and other assets	-5,004	10,750
Unrealized movements in investments and other assets	-10,625	6,911
Purchase of investments and other assets	-44,025	-52,848
Sale of investments and other assets	37,442	49,732
Change in amounts receivable	-1,468	34
Change in current liabilities	374	-1,767
	-8,665	-5,843
Cash flows from financial activities		
Issue of shares	1,822	4,988
Redemption of shares	-9,108	-5,716
Total cash flows from financial activities	-7,286	-728
Currency results on cash accounts	2,389	1,798
Net increase for the period	-13,562	-4,773
Opening balance	17,041	13,799
Closing balance	3,479	9,026
	-13,562	-4,773

SELECTED NOTES TO THE REPORT ON THE FIRST HALF OF 2017

General

LSP Life Sciences Fund N.V. (the Fund) is a public limited liability company with the status of an investment company with variable capital organised and established under the laws of the Netherlands on 18 April 2011. The Fund has its statutory seat in Amsterdam, the Netherlands. The Fund is an open-end investment fund listed on Euronext Amsterdam. The Fund is managed by LSP Advisory B.V. as sole managing director of the Fund.

The purpose of the Fund is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical, specialist pharmaceutical, medical device, drug delivery, vaccine and diagnostic companies).

The Fund qualifies as a tax-exempt investment fund within the meaning of Article 6a of the Dutch Corporate Income Tax Act. Accordingly, the Fund is not subject to Dutch corporate income tax.

Accounting principles

General

The financial year of the Fund corresponds to the calendar year. This report has been prepared in accordance with generally accepted accounting principles in the Netherlands, and in compliance with the financial reporting requirements included in Part 9, Book 2 of the Netherlands Civil Code as well as the Dutch Act on Financial Supervision.

The functional currency of the Fund is Euro and the financial statements are presented in thousands of Euro's except per share data.

Unless specifically specified otherwise the Fund applies the historical cost convention less any value adjustments deemed necessary. Furthermore, the accrual method of accounting has been applied which means that income and expenses are recognised in the period to which they relate rather than the period in which they have been paid or received.

Foreign currency translation

Unless otherwise stated, assets and liabilities denominated in foreign currencies are translated into the Fund's reporting currency at the exchange rates at closing date. Revenues and expenses denominated in foreign currencies are translated into Euro's at rate prevailing at the transaction date. Resulting currency exchange differences are taken into the Profit and Loss account under currency results.

The exchange rates at 30 June 2017, in Euro	
Danish Crown	0.13450
British Pound	1.13889
United States Dollar	0.87677
Swiss Franc	0.91554

Investments*Securities*

Investments are recorded at their fair value. The Fund only has investments in listed securities for which fair value is determined at their closing price on the valuation date on the relevant exchanges. Transaction costs in respect of purchase and sale of investments are included in unrealized and realized movements in investments.

Derivatives

Derivatives (warrants) are measured at fair value on initial recognition. After initial recognition, these derivative financial instruments are carried at fair value, with gains and losses recognized in unrealized and realized movements in investments in the Profit and Loss account.

In the absence of a quotation, the fair value of the warrants is calculated using the Black-Scholes Discrete model, taking into account the exercise price of the warrant, the remaining life of the warrant, the vesting period of the warrant, the share price of the underlying security at valuation date, the risk-free interest rate, the expected volatility and the expected dividend yield.

Receivables and other assets

Other receivables are carried at amortised cost on the basis of the effective interest method, less impairment losses. Cash and cash equivalents are stated at nominal value. If cash and cash equivalents are not readily available, this fact is taken into account in the measurement.

Share premium account

This reserve originates from the issue and redemption of shares over and above their nominal value.

Current liabilities

Current liabilities and other financial commitments are stated after their initial recognition at amortised cost on the basis of the effective interest rate method.

Profit and Loss account

Income and expenses are accounted for in the period to which they relate.

Realized movements in investments and other assets

Realized movements in investments and other assets consist of gains or losses on securities and derivate positions that have been sold during the reporting period.

Unrealized movements in investments and other assets

Unrealized movements in investments and other assets consist of gains or losses on securities and derivate positions that are (still) in the portfolio at the end of the reporting period.

Income

Dividends are recognised on an ex-dividend date basis. Dividend income is recognised net of dividend withholding tax as the fund cannot reclaim dividend tax paid from the tax authorities. If the Fund elects to receive a stock dividend in lieu of a cash dividend, an amount equal to dividends not received is included in income. When the Fund receives a stock dividend when there is no cash alternative, an amount equal to the nominal value of the shares issued is included in income to the extent that such stock dividend is regarded as revenue for Dutch tax purposes.

Expenses

Expenses are dealt with on an accrual basis. All expenses are charged to the Profit and Loss account.

Cash Flow statement

The Cash Flow statement is prepared by using the indirect method.

Notes to balance sheet


1. Investments

	30 June 2017	31 December 2016
Securities		
Market value beginning of period	42,653	85,190
Purchases	44,025	90,288
Sales	-37,442	-116,391
Unrealized price movements	11,063	2,184
Unrealized currency movements	-2,827	-1,123
Realized price movements	4,346	-17,806
Realized currency movements	658	311
Market value at end of period	62,476	42,653
Derivatives		
Market value beginning of period	-	1
Purchases	-	-
Sales	-	-
Unrealized price movements	-	-
Unrealized currency movements	-	-1
Realized price movements	-	-
Realized currency movements	-	-
Market value at end of period	-	-

The parameters used for the period end valuation of the non-listed warrants (included in derivatives) are:

Parameter	Warrant C Sphere Medical serie 1 07/15/13-07/14/18	Warrant D Sphere Medical serie 2 07/15/13-07/14/18
	Expiration date	Jul-18
Remaining life	1.04 years	1.04 years
Price of underlying share at value date	GBP 8.50	GBP 8.50
Exercise price	GBP 92.50	GBP 44.00
Vesting period	-	-
Expected dividend yield	0.00%	0.00%
Expected volatility	60.02%	60.02%
Rate of yield curve	0.56%	0.56%

The Fund's investments are classified according to stage, subsector and market capitalization. The breakdown of the Fund's portfolio per 30 June 2017 is shown below.



Stage at period end	2017 - 06	2016
Early Stage	37%	49%
Late Stage	50%	24%
Market	13%	27%

Subsector at period end	2017 - 06	2016
Therapeutics	90%	92%
Medical Device	2%	3%
Specialty Pharma	8%	5%

Marketcap at period end	2017 - 06	2016
Microcap	2%	3%
Smallcap	67%	59%
Midcap	31%	38%

Portfolio breakdown

The below table shows the portfolio breakdown of the Fund grouped per company (including warrants) as a percentage of the total Fund's Net Asset Value.

Company	Stage	Subsector	Marketcap	%
Evotec	Early	Therapeutics	Mid	10.6%
Neuroderm	Early	Therapeutics	Small	8.4%
arGEN-X	Early	Therapeutics	Small	8.1%
Morphosys	Late	Therapeutics	Mid	8.0%
Versartis	Late	Therapeutics	Small	7.6%
Clinigen Group	Market	Specialty Pharma	Small	7.5%
Aerie Pharmaceuticals	Late	Therapeutics	Mid	7.2%
CytomX Therapeutics	Early	Therapeutics	Small	6.8%
Erytech Pharma	Late	Therapeutics	Small	6.0%
Ablynx	Late	Therapeutics	Small	5.5%
Paratek Pharmaceuticals	Late	Therapeutics	Small	5.3%
Syndax Pharmaceuticals	Late	Therapeutics	Small	3.6%
GW Pharmaceuticals	Market	Therapeutics	Mid	3.3%
Zynerba Pharmaceuticals	Late	Therapeutics	Small	2.1%
Sphere Medical	Market	Medical Device	Micro	1.6%
Probiodrug	Late	Therapeutics	Small	1.3%
				93.1%

2. Other assets

Cash accounts

The cash at banks are held with KAS BANK N.V. and are available on demand. The net cash of the Fund at year end consists of a credit balance on the Euro account and a debit balance on the British Pound, Swiss Franc and United States Dollar currency accounts as shown in below table.

Cash account	at 30 June 2017		at 31 December 2016	
	in Local Currency	in Euro	in Local Currency	in Euro
Euro	41,461	41,461	49,738	49,738
Danish Crown	-	-	-21,783	-2,930
Swiss Franc	-4	-4	-4	-4
British Pound	-5,475	-6,235	-2,918	-3,418
United States Dollar	-36,205	-31,743	-27,787	-26,345
Total		3,479		17,041

The cash accounts are an integral part of the Fund's currency hedging as further detailed in note 5. Furthermore all accounts are covered by the same contractual agreements. The individual account balances are managed jointly and are presented in the annual accounts as a single netted amount.

3. Shareholders' equity

The authorized share capital of the Fund is Euro 1,000,000 and is divided in 1,000,000 shares with a par value of Euro 1.00 each. The number of issued shares at 30 June 2017 amounts to 315,311.

	30 June 2017	31 December 2016
Issued share capital		
Balance at beginning of period	353	448
Issued	9	43
Redemption	-47	-138
Balance at end of the period	315	353
Share premium account		
Balance at beginning of period	31,747	48,550
Issue of shares	1,813	7,276
Redemption of shares	-9,061	-24,079
Balance at end of the period	24,499	31,747
Other reserves		
Balance at beginning of period	45,950	35,635
Result appropriation for previous year	-18,267	10,315
Balance at end of the period	27,683	45,950
Number of issued shares		
Balance at beginning of period	352,971	448,036
Issued	9,385	43,706
Redemption	-47,045	-138,771
Balance at end of the period	315,311	352,971
Number of shares	315,311	352,971
Net Asset Value	67,138	59,783
Net Asset Value per share	212.92	169.37
Unappropriated result		
Balance at beginning of period	-18,267	10,315
Result previous year added to other reserves	18,267	-10,315
Result for the period	14,641	-18,267
Balance at end of the period	14,641	-18,267

4. Current liabilities**30 June 2017****31 December 2016****Creditors and accrued expenses**

Interest	40	35
Share redemptions payable to shareholders	226	-
Fund operational costs	175	98
Management fee	82	78
Performance fee	62	
	<hr/>	<hr/>
	585	211

The creditors and accrued expenses are payable within one year.

Fund operational costs

Fund administration fee	69	19
Remuneration of the Supervisory Board	45	30
Governance costs	3	2
Auditor's remuneration	45	33
Advisory costs	3	10
Other Costs	10	4
	<hr/>	<hr/>
	175	98

Notes to the Profit and Loss account

5. Realized and unrealized movements in investments and other assets

	30 June 2017	30 June 2016
Realized movements on securities		
Realized gains / losses on securities	4,346	-10,207
Currency results on securities	658	-543
	5,004	-10,750
Unrealized movements on securities		
Change in unrealized gains / losses on securities	11,063	-6,830
Currency results on securities	-2,827	-1,879
	8,236	-8,709

The realized and unrealized movements are a combination of gains as well as losses. In accordance with the generally accepted accounting principles in the Netherlands these gains and losses have to be reported separately. The below table provides this decomposition.

Realized movements 30 June 2017	Gains	Losses	Total
Securities	8,421	-3,417	5,004
Unrealized movements 30 June 2017	Gains	Losses	Total
Securities	11,251	-3,015	8,236
Realized movements 30 June 2016	Gains	Losses	Total
Securities	5,095	-15,845	-10,750
Unrealized movements 30 June 2016	Gains	Losses	Total
Securities	10,052	-18,761	-8,709

Currency results on cash accounts

The Fund makes use of foreign currency cash accounts to (partially) hedge the currency exposure of its investments. During the reporting period the currency results on these cash accounts amounted to a profit of Euro 2,390 thousand (H1-2016: 1,799 thousand), whilst the realized and unrealized currency result of the investments amounted to a loss of Euro 2,169 thousand (H1-2016: -2,422 thousand). The net currency result of the Fund thus amounted to a gain of Euro 221 thousand (H1-2016: -623 thousand).

6. Management costs

Management Fee

The Fund Manager is entitled to an annual management fee due by the Fund to the Fund Manager equal to 1.5% per annum of the Net Asset Value excluding (i.e. before deduction of) the accrued management fee and performance fee. The management fee accrues on a daily basis by reference to the latest Net Asset Value and is payable by the Fund in arrears as per the last business day of each month. The management fee amounts to Euro 480 thousand (H1-2016: 576 thousand).

Performance Fee

The Fund Manager is entitled to receive a performance fee of twenty per cent (20%) of the increase (if any) in the Net Asset Value per share accrued during the year for each share outstanding at the end of the relevant year, but only to the extent such increase exceeds the hurdle of 8%. The performance fee is furthermore subject to a perpetual high watermark which means that performance fee shall only be payable if, and to the extent that, the Net Asset Value per share at the end of a year is greater than the highest value of this variable which has been determined at the end of all of the preceding years. The performance fee is calculated and accrues on a daily basis. The performance fee, if any, is payable as per the last valuation day of each calendar year.

The initial issue price of Euro 100.00 per share, plus the 8% hurdle since inception amounted to Euro 161.09 at 30 June 2017. The high watermark is set to the highest Net Asset Value per share at the end of all preceding years, i.e. Euro 211.92. As the High Watermark exceeds the hurdle, the performance fee is calculated with reference to this High Watermark. The Net Asset Value per share – before performance fee – as of period-end was Euro 212.91, and thus above the High Watermark. The performance fee amounts to 20% of this excess performance, multiplied by the number of shares outstanding. This results in a performance fee for the period in the amount of Euro 62 thousand (H1-2016: 0 thousand)

(in Euro per share)	30 June 2017	30 June 2016
Net Asset Value (before performance fee)	212.91	170.17
Hurdle	161.09	149.15
High Watermark	211.92	211.92
Excess performance	0.99	0.00
Performance fee (20% of excess performance)	0.198	0.00
Number of shares outstanding	315,311	444,041

7. Depositary costs

In connection with the Alternative Investment Fund Manager Directive (AIFMD) that came in force on 22 July 2014, the Fund has appointed KAS Trust & Depositary Services B.V. as depositary. The depositary acts in the interest of the investors and is responsible for the safekeeping of the fund's assets and the oversight and supervision of the Fund and the management of the Fund by the Fund Manager. The depositary costs consist of the fees contractually due to the depositary for the provision of its services.

8. Fund operational costs	30 June 2017	30 June 2016
Fund administration fee and bank fees	118	99
Remuneration of the Supervisory Board	15	15
Governance costs	1	1
Auditor's remuneration	16	16
Advisory costs	7	7
Other costs	9	9
	166	147

Fund operational costs include all costs of legal, tax, regulatory, administrative, custody, auditing, reporting and similar services and advices provided to the Fund, the cost of the Fund Agent and Administrator, the costs of supervision of the Fund, all costs incurred in relation to the Fund's Supervisory Board and all costs of communications with and meetings of the investors.

Auditor's remuneration

The following fees were charged by KPMG Accountants N.V. to the company, its subsidiaries and other consolidated companies, as referred to in Section 2:382a (1) and (2) of the Netherlands Civil Code.

	30 June 2017		
	KPMG Accountants N.V.	Other KPMG network	Total KPMG
Audit of the financial statements	16	-	16
Other audit engagements	-	-	-
Tax-related advisory services	-	-	-
Other non-audit services	-	-	-
	-	-	16

	30 June 2016		
	KPMG Accountants N.V.	Other KPMG network	Total KPMG
Audit of the financial statements	16	-	16
Other audit engagements	-	-	-
Tax-related advisory services	-	-	-
Other non-audit services	-	-	-
	-	-	16

Remuneration policy

The Fund itself has no employees. The management of the Fund is entrusted to the Fund Manager being LSP Advisory B.V. As such the remuneration policy is determined at the level of the Fund Manager. The Fund Manager has implemented the AIFMD regulations regarding remuneration and has established a compliant remuneration policy. The objective of this remuneration policy is to motivate and retain the investment managers and other employees. The remuneration policy of the Fund Manager is designed such that it is consistent with and promotes sound and effective risk management and does not encourage risk-taking in a manner inconsistent with the risk policy of the Fund. The remuneration policy is reviewed on annual basis and will be amended from time to time to remain compliant with applicable regulations and to abide by social norms. The remuneration consists of a fixed and a variable component. The variable remuneration is linked to the performance of the Fund as well as to the individual targets of the staff members.

Remuneration of the Fund Manager's staff

During the first half of 2017 the Fund Manager paid Euro 0.5 million (H1-2016: 0.4 million) to its staff members. Of this amount Euro 0.5 million (H1-2016: 0.4 million) was fixed remuneration and nil (H1-2016: nil) was variable.

Of the total remuneration referenced above an amount of Euro 0.4 million (H1-2016: 0.4 million) related to the directors of the Fund Manager. This consists of a fixed remuneration of Euro 0.4 million (H1-2016: 0.4 million) and no variable compensation for the period (H1-2016: nil).

In total 5 staff members work in part or fully for the Fund. The total remuneration of these staff members that is attributed to managing the Fund for the period amounts to Euro 0.5 million (H1-2016: 0.4 million), such amount being allocated on the basis of the average Assets under Management of the various activities of LSP Advisory B.V. The tables on the next page show the breakdown of the remuneration of the staff members attributed to the management of the Fund for the current and prior period.

H1-2017	Beneficiaries	Fixed remuneration	Variable remuneration	Total Remuneration
Directors	3	405,973	-	405,973
Identified staff	1	11,413	-	11,413
Other employees	1	52,110	-	52,110
Total	5	469,496	-	469,496

H1-2016	Beneficiaries	Fixed remuneration	Variable remuneration	Total Remuneration
Directors	3	355,951	-	355,951
Identified staff	1	11,176	-	11,176
Other employees	1	53,066	-	53,066
Total	5	420,193	-	420,193

Remuneration of the Supervisory Board

The total of remuneration for the members of the Supervisory Board for the period amounts to Euro 15 thousand (H1-2016: 15 thousand).

Supervisory Board member	30 June 2017	30 June 2016
Pauline Bieringa	9	9
Onno Paymans	6	6
	15	15

Risk factors and risk management

An investment in the Fund involves certain risks and uncertainties relating to the Fund's structure and investment strategy. The Fund has exposure to the following risks from financial instruments:

- Market risks
- Liquidity risk
- Counterparty risk, including settlement risk
- Operational risks, including preservation and legal and tax compliance risks

The Fund Manager applies a comprehensive process based on qualitative and quantitative risk measures to assess the risks of the Fund entailing a standard monitoring process which consists of pre-defined monitoring items and cycles. The overall exposure of the Fund is calculated by means of the Value-at-Risk (VaR) methodology. The Value-at-Risk methodology provides a measure of the potential loss that could arise over a given time interval under normal market conditions, and at a given confidence level. During the first half year of 2017 no risk limits of the Fund have been exceeded nor were they likely to be exceeded.

The Fund Manager has been given a discretionary authority to manage the assets in accordance with the Fund's investment objectives. Compliance with the investment restrictions and the composition of the portfolio is monitored by the Fund Manager on a daily basis.

Market Risk

The prices of financial instruments on the financial markets in general and more specifically the prices of financial instruments in the portfolio can increase or decrease as a result of a multitude of factors like expectations of economic growth, inflation and price movements of goods and foreign currencies. In addition the value of the portfolio can vary due to, for example, political and monetary developments. Market risks are increased as a result of limiting the geographic scope of the Fund to Europe (and in part to the United States) as well as the Fund's concentrated sector portfolio. The Fund manager distinguishes the following market risks: (i) price volatility, (ii) concentration risk, (iii) foreign currency risk and (iv) interest rate risk, which are discussed in further detail below.

(i) Price volatility

The stock prices of companies involved in the life sciences industry have been and will likely continue to be volatile. Stock prices and their related financial instruments (e.g. warrants) could be subject to wide fluctuations in response to a variety of factors, including the following:

- General market fluctuations (including the parameters used for valuation of warrants);
- Actual or anticipated variations in companies' operating results;
- Announcements of technological innovations by competitors;
- Changes in financial estimates by securities analysts;
- Changes in the market valuations of life sciences companies;
- Legal or regulatory developments affecting companies in the life sciences industry;
- Announcement by life sciences companies or their competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; or
- Additions or departures of key personnel.

Many life sciences companies do not or in the future might not have earnings. As a result, the trading prices of life sciences companies may decline substantially and valuations may not be sustained. Any negative change in the public's perception of the prospects of life sciences companies, generally could depress the stock prices of a particular company regardless of its results. Other broad market and industry factors may decrease the stock price of life sciences stocks, regardless of their operating results.

Market fluctuations, as well as general political and economic conditions such as recession or interest rate or currency rate fluctuations, also may decrease the market price of life sciences stocks. Given the investment objective of the Fund and its inherent sector focus, the price volatility risk is in principle not managed by the Fund Manager.

(ii) Concentration risk

The Fund endeavours to create a concentrated portfolio of life sciences investments that are diversified by sub-sector (indication area or technology), geographic location, type of investment (IPOs, rights offerings, follow-on offerings, PIPEs, direct equity offerings, open market transactions, etc.), business model, area of focus, stage of development, etc. in order to achieve a high level of risk diversification. However, subject to the investment restrictions, investments may be weighted to certain indication and/or technologies and in certain geographic markets within Europe. Events that impact a specific investment, a specific sub-sector or a region may have an impact on the Fund's performance. The investment restrictions put an upper limit to the maximum allocation to a single portfolio company. Furthermore the Fund Manager monitors the concentration levels on a daily basis and will rebalance the portfolio if so required. As at 30 June 2017 the 5 single largest holdings account for 43% of the Net Asset Value of the Fund (year-end 2016: 39%).

(iii) Foreign currency risk

The Fund invests in life sciences companies in various countries. The investments may be dominated in currencies other than Euro and the value of these currencies may fluctuate. Thus, investors in principle will be subject to fluctuations in currency exchange rates. These fluctuations may have a positive or a negative effect on the Net Asset Value. The Fund Manager can make use of a range of financial instruments to (partially) hedge the various currency exposures that result from the portfolio investments. During the reporting period the currency risk of the British Pound, Danish Crown and United States Dollar was partially hedged by contrary positions on the respective foreign currency cash accounts.

Net currency exposure	at 30 June 2017		at 31 December 2016	
	in Local Currency	in Euro	in Local Currency	in Euro
Swiss Franc	-4	-4	-4	-4
Danish Crown	-	-	650	87
British Pound	-135	-154	-63	-73
United States Dollar	-2,187	-1,917	-596	-565

(iv) Interest rate risk

The Fund has no significant exposure to interest rate risk, since all cash accounts have floating interest rates and the Fund does not hold any fixed income securities.

Liquidity risk

Liquidity risk is the risk that the Fund will encounter difficulty in meeting obligations arising from its financial liabilities – including redemptions of shares – that are settled by delivering cash or another financial asset, or that such obligations will have to be settled in a manner disadvantageous to the Fund. The Fund Manager actively monitors the maximum possible share redemptions in relation to the Fund's cash position and the level of liquidity of securities in the portfolio and will take corrective action if so required.

Counterparty risk

The Fund can be subject to the risk of the inability or refusal of dealers, brokers, clearing and payment institutions, custodians, principals or other service providers, issuing entities or other counterparties to its transactions to duly and timely perform under such services or transactions. Any such shortcoming, failure or refusal, whether due to insolvency, bankruptcy or other causes, could subject the Fund to substantial losses. The Fund Manager mitigates these risks by reviewing the creditworthiness and reliability of all service providers and counterparties and only enters into transactions with those parties that the Fund believes to be creditworthy and reliable. All cash balances, amounting to Euro 3,479 thousand as at 30 June 2017 (year-end 2016: 17,041 thousand), are held with the KAS BANK N.V. Fitch ratings has affirmed KAS BANK N.V.'s (per 16 December 2016) long- and Short-Term Issuer Default Ratings (IDRs) at 'A-' and 'F2', respectively. The outlook on the Long-Term IDR is Stable.

Settlement risk

The Fund can be subject to the risk that settlement through a payment system is unable to take place as expected because payment or delivery of the financial instruments is not on time or does not happen at all. The Fund mitigates this risk by conducting most of its settlements through a broker and ensuring that a trade is settled only when both parties have fulfilled their contractual settlement obligations.

Operational risks

Operational risk concerns the risk that the Fund will incur financial losses due to amongst others operational errors, negligence and/or fraud. In general the Fund manages this risk through an adequate administrative organization including segregation of duties and internal controls, which cover these risks.

Preservation risk

To safeguard the assets of the Fund, the Fund uses an independent custodian. Preservation risk is the risk that the assets of the Fund are lost as a result of, among other things, negligence, insolvency or fraudulent actions of the custodian. To monitor and mitigate this risk, the Fund Manager will periodically review the ISAE 3402 Type II report as received from the custodian to assess whether the relevant administrative organization and internal controls are adequate.

Legal and tax compliance risks

Changes in tax legislation in any of the countries in which the Fund has investments, or changes in tax treaties negotiated by those countries, could adversely affect the returns from the Fund to its investors. In the event that the Fund no longer complies with the requirements of a tax-exempt investment fund, the Fund might be subject to Dutch corporate income tax. The Fund Manager, in consultation with its tax and legal advisors, monitors compliance with the relevant rules and regulations.

Transactions with related parties

The Fund Manager, LSP Advisory B.V. qualifies as a related party. In the reporting period the Fund Manager received a management fee of Euro 480 thousand (H1-2016: 576 thousand) and for the reporting period a performance fee of Euro 62 thousand is accrued (H1-2016: 0). Employees of the Fund Manager, LSP or its affiliates participate in the Fund against a market price.

Soft dollar arrangements

The Fund will not enter into arrangements with any party regarding kickback payments. Third parties may in relation to the execution of orders by them on behalf of the Fund provide products and services to the Fund manager. During the reporting period the Fund's transactions were conducted under execution-only arrangements with its brokers and the Fund manager has assessed that it received no soft dollar arrangement during the first half of 2017 (H1-2016: none).

Interests of the Supervisory Board and Management

The members of the Supervisory Board and Management had no interests in securities held by the Fund's portfolio as at 30 June 2017 (year-end 2016: no interests).

The members of the Supervisory Board had no shares in the Fund as at 30 June 2017 (year-end 2016: no shares).

Employees of the Fund Manager, LSP or its affiliates participate in the Fund against a market price. These persons own in aggregate 14,615 (year-end 2016: 14,575) shares in the Fund. The lock-up period as described in the prospectus of the Fund has expired.

Amsterdam, 31 August 2017

The director

LSP Advisory B.V.

OTHER INFORMATION

Statutory income allocation

According to article 22 of the Articles of Association, the Fund Manager will determine which part of the profit will be retained; the remainder of the profit will be at the disposal of the general meeting of shareholders.

Distributions policy

As the investment objective of the Fund is to achieve capital appreciation, frequent and regular distribution of profits or other net proceeds by the Fund are not intended nor anticipated. All net proceeds will in principle be reinvested and the Fund Manager will exercise its right to add profits of the Fund to the Fund's reserves.

Post-balance sheet events

There were no material post-balance sheet events which have a bearing on the understanding of the financial statements.

STATEMENT OF THE DEPOSITARY

Considering that

- KAS Trust & Depositary Services B.V. (“the depositary”) is appointed to act as depositary of **LSP Life Sciences Fund N.V.** (“the fund”) in accordance with section 21(1) of the Alternative Investment Fund Managers Directive (2011/61/EU) (the “AIFM Directive”);
- Such appointment and the mutual rights and obligations of the fund manager and the depositary of the fund have been agreed upon in the depositary agreement dated 22 July 2014 between such parties, including the schedules to that agreement (the “depositary agreement”);
- The depositary issues this statement exclusively to the fund manager in relation to the activities of the fund manager and relates to the period 1 January up to and including 30 June 2017, (“the reporting period”).

Responsibilities of the depositary

The depositary acts as a depositary within the meaning of the AIFM Directive and provide its services in accordance with the AIFM Directive, the EU implementing regulation, applicable Dutch laws and regulations and the policy rules issued by the European Securities and Markets Authority and the Netherlands Authority for the Financial Markets (the “regulations”). The responsibilities of the depositary have been described in the depositary agreement and include, in addition to the safekeeping, recordkeeping and ownership verification tasks (as defined in article 21(8) AIFM Directive), several monitoring and oversight tasks (as defined in article 21(7) and 21(9) AIFM Directive):

- Monitoring of the fund’s cash flows, including identification of significant and inconsistent cash flows and reconciliation of the cash flows with the fund’s administration;
- Ensuring that the sale, issue, re-purchase, redemption, cancellation and valuation of units or shares of the fund are carried out in accordance with the applicable national law and the fund documentation;
- Ensuring that in transactions involving the fund’s assets any consideration is remitted to the fund within the usual time limits;
- Ensuring that the fund’s income is applied in accordance with the applicable national law and the fund documents;
- Monitoring whether the fund is managed in compliance with the investment restrictions and leverage limits as defined in the fund documentation.

Statement of the Depositary

The depositary has carried out such activities during the reporting period as considered necessary to fulfil its responsibilities as depositary of the fund. The depositary is of the opinion that, based on the information made available to it and the explanations provided by the fund manager, in all material respects, the fund manager has carried out its activities which are in scope of the monitoring and oversight duties of the depositary, in accordance with the regulations and the fund documentation.

Miscellaneous

This statement does not create, and is not intended to create, any right for a person or an entity that is not a party to the depositary agreement.

Amsterdam, 31 August 2017

KAS Trust & Depositary Services B.V.